201 related articles for article (PubMed ID: 12068339)
21. Effects of salmeterol on sleeping oxygen saturation in chronic obstructive pulmonary disease.
Ryan S; Doherty LS; Rock C; Nolan GM; McNicholas WT
Respiration; 2010; 79(6):475-81. PubMed ID: 19684384
[TBL] [Abstract][Full Text] [Related]
22. Long-acting beta2-agonists for chronic obstructive pulmonary disease.
Appleton S; Smith B; Veale A; Bara A
Cochrane Database Syst Rev; 2000; (2):CD001104. PubMed ID: 10796594
[TBL] [Abstract][Full Text] [Related]
23. Onset of action of formoterol versus salmeterol via dry powder inhalers in moderate chronic obstructive pulmonary disease: a randomized, placebo-controlled, double-blind, crossover study.
Cazzola M; Paggiaro P; Palange P; Bjermer L; Ausin P; Carlsson LG; Ekelund J; Lotvall J
Clin Drug Investig; 2012 Mar; 32(3):147-55. PubMed ID: 22235841
[TBL] [Abstract][Full Text] [Related]
24. Acute effects of higher than customary doses of salmeterol and salbutamol in patients with acute exacerbation of COPD.
Cazzola M; Califano C; Di Perna F; D'Amato M; Terzano C; Matera MG; D'Amato G; Marsico SA
Respir Med; 2002 Oct; 96(10):790-5. PubMed ID: 12412978
[TBL] [Abstract][Full Text] [Related]
25. Comparison of the efficacy of formoterol and salmeterol in patients with reversible obstructive airway disease: a multicenter, randomized, open-label trial.
Condemi JJ
Clin Ther; 2001 Sep; 23(9):1529-41. PubMed ID: 11589265
[TBL] [Abstract][Full Text] [Related]
26. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial.
Lapperre TS; Snoeck-Stroband JB; Gosman MM; Jansen DF; van Schadewijk A; Thiadens HA; Vonk JM; Boezen HM; Ten Hacken NH; Sont JK; Rabe KF; Kerstjens HA; Hiemstra PS; Timens W; Postma DS; Sterk PJ;
Ann Intern Med; 2009 Oct; 151(8):517-27. PubMed ID: 19841453
[TBL] [Abstract][Full Text] [Related]
27. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease.
Vestbo J; Pauwels R; Anderson JA; Jones P; Calverley P;
Thorax; 2005 Apr; 60(4):301-4. PubMed ID: 15790985
[TBL] [Abstract][Full Text] [Related]
28. Comparable spirometric efficacy of tiotropium compared with salmeterol plus fluticasone in patients with COPD: a pilot study.
Bateman ED; van Dyk M; Sagriotis A
Pulm Pharmacol Ther; 2008; 21(1):20-5. PubMed ID: 17118684
[TBL] [Abstract][Full Text] [Related]
29. Addition of an extra dose of salmeterol Diskus to conventional dose of salmeterol Diskus in patients with COPD.
Cazzola M; Santus P; Castagna F; Di Marco F; Terzano C; Matera MG; Centanni S
Respir Med; 2002 Jun; 96(6):439-43. PubMed ID: 12117044
[TBL] [Abstract][Full Text] [Related]
30. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD).
Boyd G; Morice AH; Pounsford JC; Siebert M; Peslis N; Crawford C
Eur Respir J; 1997 Apr; 10(4):815-21. PubMed ID: 9150318
[TBL] [Abstract][Full Text] [Related]
31. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial.
Calverley P; Pauwels R; Vestbo J; Jones P; Pride N; Gulsvik A; Anderson J; Maden C;
Lancet; 2003 Feb; 361(9356):449-56. PubMed ID: 12583942
[TBL] [Abstract][Full Text] [Related]
32. Comparison of dry powder versus nebulized beta-agonist in patients with COPD who have suboptimal peak inspiratory flow rate.
Mahler DA; Waterman LA; Ward J; Gifford AH
J Aerosol Med Pulm Drug Deliv; 2014 Apr; 27(2):103-9. PubMed ID: 23745526
[TBL] [Abstract][Full Text] [Related]
33. Parasternal muscle activity decreases in severe COPD with salmeterol-fluticasone propionate.
Easton PA; Hawes HG; Doig CJ; Johnson MW; Yokoba M; Wilde ER
Chest; 2010 Mar; 137(3):558-65. PubMed ID: 19820074
[TBL] [Abstract][Full Text] [Related]
34. A double-blind crossover study comparing the safety and efficacy of three weeks of Flu/Sal 250/50 bid plus albuterol 180 ug prn q4 hours to Flu/Sal 250/50 bid plus albuterol/Ipratropium bromide 2 puffs prn q4 hours in patients with chronic obstructive pulmonary disease.
Balkissoon R; Make B
COPD; 2008 Aug; 5(4):221-7. PubMed ID: 18671147
[TBL] [Abstract][Full Text] [Related]
35. Efficacy, tolerability, and effects on quality of life of inhaled salmeterol and oral theophylline in patients with mild-to-moderate chronic obstructive pulmonary disease. SLMT02 Italian Study Group.
Di Lorenzo G; Morici G; Drago A; Pellitteri ME; Mansueto P; Melluso M; Norrito F; Squassante L; Fasolo A
Clin Ther; 1998; 20(6):1130-48. PubMed ID: 9916607
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease.
Mahler DA; Wire P; Horstman D; Chang CN; Yates J; Fischer T; Shah T
Am J Respir Crit Care Med; 2002 Oct; 166(8):1084-91. PubMed ID: 12379552
[TBL] [Abstract][Full Text] [Related]
37. Ipratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease.
Appleton S; Jones T; Poole P; Pilotto L; Adams R; Lasserson TJ; Smith B; Muhammad J
Cochrane Database Syst Rev; 2006 Jul; 2006(3):CD006101. PubMed ID: 16856113
[TBL] [Abstract][Full Text] [Related]
38. Cardiovascular safety of salmeterol in COPD.
Ferguson GT; Funck-Brentano C; Fischer T; Darken P; Reisner C
Chest; 2003 Jun; 123(6):1817-24. PubMed ID: 12796155
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
Kerwin EM; Gotfried MH; Lawrence D; Lassen C; Kramer B
Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
[TBL] [Abstract][Full Text] [Related]
40. Study design considerations in a large COPD trial comparing effects of tiotropium with salmeterol on exacerbations.
Beeh KM; Hederer B; Glaab T; Müller A; Rutten-van Moelken M; Kesten S; Vogelmeier C
Int J Chron Obstruct Pulmon Dis; 2009; 4():119-25. PubMed ID: 19436693
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
